Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3)

Alan F. Cohen, Christopher J. Hartnick, Richard V. Smith

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Reversible and irreversible ototoxicity has been documented following the administration of various therapeutic agents. Reversible hearing loss is a known complication folio wing the administration of quinine, salicylates and other nonsteroidal anti-inflammatory drugs, and erythromycin. We report a case of reversible hearing loss following OKT3 (murine monoclonal antibody CD3) administration. OKT3, a monoclonal antibody used as an immunosuppressant following cadaveric renal transplants, was associated with a transient sensorineural hearing loss that reversed following discontinuation of OKT3.

Original languageEnglish (US)
Pages (from-to)640-642
Number of pages3
JournalAnnals of Otology, Rhinology and Laryngology
Volume106
Issue number8
DOIs
StatePublished - 1997

Keywords

  • Immunosuppression
  • OKT3
  • Sensorineural hearing loss
  • Transplant

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Reversible sensorineural hearing loss after renal transplant immunosuppression with OKT3 (muromonab-CD3)'. Together they form a unique fingerprint.

  • Cite this